Back to results
US 12,714,697 B2Granted
Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
AssigneeTravere Therapeutics, Inc.
InventorsRadko Komers, Alvin Shih
Life of this patent
Estimating the term…
Abstract
Methods of treatment comprising administering a compound having structure (I), or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition comprising the compound of structure (I) or pharmaceutically acceptable salt thereof, are provided.
Claims27
A method of treating a subject with IgA nephropathy (IgAN) comprising
- (i) orally administering an initial dose of 200 mg of sparsentan to the subject once a day for a period of 14 days;
- and
- (ii) after the initial 14-day period, orally administering a subsequent dose of 400 mg of sparsentan to the subject once a day,
- wherein said subject has a baseline UP/C ratio greater than 1.0 g/g, and
- wherein the subject's UP/C ratio is reduced by 40% or more relative to the subject's baseline UP/C ratio within the first 36 weeks of treatment.
2 more elements
A method of slowing kidney function decline in a subject with IgA nephropathy (IgAN) comprising
- (i) orally administering an initial dose of 200 mg of sparsentan to the subject once a day for a period of 14 days;
- and
- (ii) after the initial 14-day period, orally administering a subsequent dose of 400 mg of sparsentan to the subject once a day,
- wherein said subject has a baseline urine protein to creatinine (UP/C) ratio greater than 1.0 g/g, and
- wherein the subject's UP/C ratio is reduced by 40% or more relative to the subject's baseline UP/C ratio within the first 36 weeks of treatment.
2 more elements
A method of reducing proteinuria in subject with IgA nephropathy (IgAN) comprising
- (i) orally administering an initial dose of 200 mg of sparsentan to the subject once a day for a period of 14 days;
- and
- (ii) after the initial 14-day period, orally administering a subsequent dose of 400 mg of sparsentan to the subject once a day,
- wherein said subject has a baseline UP/C ratio greater than 1.0 g/g;
- and
- wherein the subject's urine protein to creatinine (UP/C) ratio is reduced by 40% or more relative to the subject's baseline UP/C ratio within the first 36 weeks of treatment.
3 more elements
Dependencies are inferred from the claim text.